Physician profile
Mark Motejunas
NPI 1093165789
$4,177.64
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $773 · 2021: $1,479 · 2022: $1,733 · 2023: $66.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $66.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $66.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,650.66 | 2021-2022 | |
| Boston Scientific Corporation | $1,158.95 | 2020-2021 | |
| Nalu Medical, INC. | $441.63 | 2020-2022 | |
| Avanos Medical | $156.64 | 2021 | |
| Nevro Corp. | $125.45 | 2019 | |
| Ucb, INC. | $109.53 | 2022-2023 | Briviact |
| Vertos Medical, INC. | $95.15 | 2021 | |
| Medtronic USA, INC. | $69.34 | 2020 | |
| Masimo Corporation | $58.23 | 2021 | |
| Arbor Pharmaceuticals, INC. | $53.65 | 2021 | |
| Almatica Pharma LLC | $51.28 | 2021 | |
| Spr Therapeutics, INC | $30.63 | 2022 | |
| Alexion Pharmaceuticals, INC. | $29.50 | 2022 | |
| Merck Sharp & Dohme LLC | $28.69 | 2020-2021 | |
| Eisai INC. | $24.51 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stimwave Technologies Incorporated | $23.68 | 2021 | |
| Collegium Pharmaceutical, INC. | $21.13 | 2021 | |
| Amgen INC. | $17.44 | 2021 | |
| Avanir Pharmaceuticals, INC. | $16.52 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Motejunas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.